SG11202112909SA - Method of providing safe administration of an anti-cd40 antibody - Google Patents
Method of providing safe administration of an anti-cd40 antibodyInfo
- Publication number
- SG11202112909SA SG11202112909SA SG11202112909SA SG11202112909SA SG11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA SG 11202112909S A SG11202112909S A SG 11202112909SA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- providing safe
- safe administration
- administration
- providing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853488P | 2019-05-28 | 2019-05-28 | |
| PCT/IB2020/055023 WO2020240434A1 (en) | 2019-05-28 | 2020-05-27 | Method of providing safe administration of an anti-cd40 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112909SA true SG11202112909SA (en) | 2021-12-30 |
Family
ID=70918772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112909SA SG11202112909SA (en) | 2019-05-28 | 2020-05-27 | Method of providing safe administration of an anti-cd40 antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230174658A1 (en) |
| EP (1) | EP3976651A1 (en) |
| JP (1) | JP2022534494A (en) |
| KR (1) | KR20220012918A (en) |
| CN (1) | CN113939535A (en) |
| AU (1) | AU2020284706A1 (en) |
| BR (1) | BR112021023906A2 (en) |
| CA (1) | CA3142226A1 (en) |
| IL (1) | IL288288A (en) |
| MA (1) | MA56027A (en) |
| MX (1) | MX2021014572A (en) |
| SG (1) | SG11202112909SA (en) |
| WO (1) | WO2020240434A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122355A2 (en) * | 2021-12-24 | 2023-06-29 | Sapience Therapeutics, Inc. | Methods of treating or preventing infusion-related reactions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| MX2017001864A (en) * | 2014-08-12 | 2017-08-02 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies. |
| US10857230B2 (en) * | 2017-03-03 | 2020-12-08 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer |
-
2020
- 2020-05-27 MX MX2021014572A patent/MX2021014572A/en unknown
- 2020-05-27 EP EP20729226.9A patent/EP3976651A1/en active Pending
- 2020-05-27 MA MA056027A patent/MA56027A/en unknown
- 2020-05-27 US US17/613,632 patent/US20230174658A1/en active Pending
- 2020-05-27 JP JP2021570263A patent/JP2022534494A/en active Pending
- 2020-05-27 CA CA3142226A patent/CA3142226A1/en active Pending
- 2020-05-27 AU AU2020284706A patent/AU2020284706A1/en active Pending
- 2020-05-27 KR KR1020217042271A patent/KR20220012918A/en unknown
- 2020-05-27 SG SG11202112909SA patent/SG11202112909SA/en unknown
- 2020-05-27 CN CN202080039748.6A patent/CN113939535A/en active Pending
- 2020-05-27 WO PCT/IB2020/055023 patent/WO2020240434A1/en unknown
- 2020-05-27 BR BR112021023906A patent/BR112021023906A2/en unknown
-
2021
- 2021-11-22 IL IL288288A patent/IL288288A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230174658A1 (en) | 2023-06-08 |
| EP3976651A1 (en) | 2022-04-06 |
| IL288288A (en) | 2022-01-01 |
| CN113939535A (en) | 2022-01-14 |
| WO2020240434A1 (en) | 2020-12-03 |
| KR20220012918A (en) | 2022-02-04 |
| MA56027A (en) | 2022-04-06 |
| JP2022534494A (en) | 2022-08-01 |
| AU2020284706A1 (en) | 2021-12-16 |
| MX2021014572A (en) | 2022-03-17 |
| CA3142226A1 (en) | 2020-12-03 |
| BR112021023906A2 (en) | 2022-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3618871A4 (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| EP3212230A4 (en) | Dosage and administration of non-fucosylated anti-cd40 antibodies | |
| AU2017435893B2 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| IL279662A (en) | Methods for the administration of certain vmat2 inhibitors | |
| AU2018296471A1 (en) | Method for authorizing operation permissions of form field values | |
| GB2585307B (en) | Methods and apparatus for assembly of moment connection components | |
| EP3145562A4 (en) | Apparatus and method for the preparation and administration of blood components | |
| IL287902A (en) | Methods for the administration of certain vmat2 inhibitors | |
| EP3279181A4 (en) | Mixture of polymerizable compound and method for producing same | |
| EP3399996A4 (en) | Methods of administering hepcidin | |
| EP3297684A4 (en) | Infusion administration of conjugated monoclonal antibodies | |
| EP3432925A4 (en) | Administration of an anti-lgr5 monoclonal antibody | |
| EP3893931A4 (en) | Methods of using anti-trem2 antibodies | |
| EP3842426A4 (en) | Preparation method of pyrrolo-amino-pyridazinone compound and intermediate thereof | |
| EP3654193A4 (en) | Method for authorizing field value of form field by means of third party field | |
| EP3696168A4 (en) | Method for preparation of 2-chloro-5-trifluoromethylpyridine | |
| IL288288A (en) | Method of providing safe administration of an anti-cd40 antibody | |
| EP3947448A4 (en) | Method of administration of an anti-ifn-alpha/-omega antibody | |
| EP3766874A4 (en) | Preparation method for hexahydrofuro-furan-ol derivative and intermediate of derivative and preparation method therefor | |
| EP3589321A4 (en) | Method and compound for modifying circadian clock | |
| EP3437681A4 (en) | Medicine administering apparatus, method of using medicine administering apparatus, and method for manufacturing medicine administering apparatus | |
| EP3856246A4 (en) | Method of providing safe administration of an anti-cd154 antibody | |
| IL280642A (en) | Method of preparing an antibody pharmaceutical formulation | |
| IL284086A (en) | Controlled fucosylation of antibodies | |
| IL280312A (en) | Process for the preparation of bromodomain inhibitor |